Eli Lilly and Company and Nvidia, the high-tech giant and producer of graphics processing units, systems on chips, and application programming interfaces for data science, high-performance/accelerated computing, and artificial intelligence (AI), have announced an AI co-innovation lab focused on applying AI to the pharmaceutical industry, in a deal worth up to $1 billion.

The lab brings together Lilly’s expertise in discovering, developing, and manufacturing medicines with Nvidia’s leadership in AI, accelerated computing, and AI infrastructure. The two companies will invest up to $1 billion in talent, infrastructure and computing over five years to support the new AI co-innovation lab.

Based in the San Francisco Bay Area, the lab will co-locate Lilly domain experts in biology, science and medicine with AI model builders and engineers from Nvidia, allowing them to generate large-scale data and build AI models that can accelerate medicine development, using Nvidia’s BioNeMo as the platform.

The collaboration will initially focus on creating a continuous learning system that tightly connects Lilly’s agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists.

The new initiative expands on Lilly’s previously announced AI supercomputer as well as the AI factory Lilly announced last fall (fall 2025).

Source: Eli Lilly and Company